Home / Market Reports / Pharma & Healthcare / Global Low Molecular Weight Heparin API Market Growth 2024-2030

Global Low Molecular Weight Heparin API Market Growth 2024-2030

Global Low Molecular Weight Heparin API Market Growth 2024-2030

Product Code:983233

Published Date: Oct 11,2024

Pages: 110

Region: Global

Category: Pharma & Healthcare

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

PDF DOWNLOAD

GET FREE SAMPLE

CUSTOMIZE REQUEST

SELECT A FORMAT

ADD TO BASKET

BUY NOW

Provide comprehensive and accurate analysis and reports according to your exact requirements

Provide comprehensive and accurate analysis and reports according to your exact requirements

CONTACT US 

Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the low molecular weight heparin API.  
The global Low Molecular Weight Heparin API market size is projected to grow from US$ 764 million in 2024 to US$ 1563 million in 2030; it is expected to grow at a CAGR of 12.7% from 2024 to 2030.

LP Information, Inc. (LPI) ' newest research report, the “Low Molecular Weight Heparin API Industry Forecast” looks at past sales and reviews total world Low Molecular Weight Heparin API sales in 2023, providing a comprehensive analysis by region and market sector of projected Low Molecular Weight Heparin API sales for 2024 through 2030. With Low Molecular Weight Heparin API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Low Molecular Weight Heparin API industry.

This Insight Report provides a comprehensive analysis of the global Low Molecular Weight Heparin API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Low Molecular Weight Heparin API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Low Molecular Weight Heparin API market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Low Molecular Weight Heparin API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Low Molecular Weight Heparin API.

The Low Molecular Weight Heparin (LMWH) API market plays a crucial role in the global pharmaceutical industry due to the widespread use of LMWHs in the prevention and treatment of blood clot-related disorders, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). LMWH APIs are preferred in clinical settings for their favorable pharmacological properties, including better bioavailability, longer half-life, and reduced risk of side effects compared to unfractionated heparin. The increasing prevalence of cardiovascular diseases and venous thromboembolism, aging populations, and a rise in surgical procedures worldwide have significantly driven demand for LMWH-based therapies.

The global market for Low Molecular Weight Heparin API was estimated to be worth US$ 0.78 billion in 2024 and is forecast to a readjusted size of US$ 1.56 billion by 2030 with a CAGR of 12.21% during the forecast period 2024-2030.

The North American and European markets lead in demand due to a high prevalence of thrombosis-related conditions and advanced healthcare infrastructure. Asia-Pacific is emerging as a growth market, driven by increased healthcare spending and the rise of generics. North American market for Low Molecular Weight Heparin API was valued at $ 294.19 million in 2023 and will reach $ 523.34 million by 2030, at a CAGR of 12.54% during the forecast period of 2024 through 2030. Asia-Pacific market for Low Molecular Weight Heparin API was valued at $ 293.62 million in 2023 and will reach $ 496.95 million by 2030, at a CAGR of 12.81% during the forecast period of 2024 through 2030. Europe market for Low Molecular Weight Heparin API was valued at $ 307.93 million in 2023 and will reach $ 521.29 million by 2030, at a CAGR of 11.45% during the forecast period of 2024 through 2030.

Low Molecular Weight Heparin API segment market, the Enoxaparin Sodium holds an important share, and it is expected to reach a value of US$ 1,258.82 million by 2030, at a CAGR of 12.46% during 2024 and 2030.

The global key companies of Low Molecular Weight Heparin API include Yantai Dongcheng Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Changzhou Qianhong Biopharma, and Qingdao Jiulong Biopharmaceutical, etc. In 2023, the global five largest players hold a share approximately 72.91% in terms of revenue.

This report presents a comprehensive overview, market shares, and growth opportunities of Low Molecular Weight Heparin API market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
    Low Molecular Weight Heparin Sodium
    Low Molecular Weight Heparin Calcium

Segmentation by Application:
    Enoxaparin Sodium
    Nadroparin Calcium
    Dalteparin Sodium
    Tinzaparin Sodium
    Parnaparin Sodium

This report also splits the market by region:
    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
    Yantai Dongcheng Pharmaceutical
    Shenzhen Hepalink Pharmaceutical
    Nanjing King-friend
    Changzhou Qianhong Biopharma
    Qingdao Jiulong Biopharmaceutical
    Dongying Tiandong Pharmaceutical
    Yino Pharma
    Opocrin
    Hebei Changshan
    Hubei Enoray Biopharmaceutical
    Nanjing Nanda Pharmaceutical
    Cisen Pharmaceutical

Key Questions Addressed in this Report
What is the 10-year outlook for the global Low Molecular Weight Heparin API market?
What factors are driving Low Molecular Weight Heparin API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Low Molecular Weight Heparin API market opportunities vary by end market size?
How does Low Molecular Weight Heparin API break out by Type, by Application?